藥明康德(02359.HK)回覆非公開發行股票發審委會議工作告知函
格隆匯 7 月 28日丨藥明康德(02359.HK)公告,無錫藥明康德新藥開發股份有限公司(以下簡稱“公司”)於2020年7月24日收到中國證券監督管理委員會(以下簡稱“中國證監會”)下發的《關於請做好無錫藥明康德新藥開發股份有限公司非公開發行股票發審委會議準備工作的函》(以下簡稱“告知函”)。
公司及相關中介機構就告知函提出的事項進行了認真研究和落實,並按照告知函的要求對所涉及的事項進行了説明和回覆,現根據相關要求對告知函的回覆進行公開披露,具體內容詳見公司同日在上海證券交易所網站(www.sse.com.cn)及指定媒體披露的《無錫藥明康德新藥開發股份有限公司、華泰聯合證券有限責任公司關於<關於請做好無錫藥明康德新藥開發股份有限公司非公開發行股票發審委會議準備工作的函>的回覆》。
公司本次非公開發行A股股票事項尚需獲得中國證監會核准,該事項能否獲得核准及最終獲得核准的時間均存在不確定性。公司將根據事項的進展情況及時履行信息披露義務。敬請廣大投資者關注後續公告,並注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.